Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tectonic Therapeutic, Inc. (TECX : NSDQ)

• Company Description    Tectonic Therapeutic Inc. is a biotechnology company developing GPCR -targeted therapeutic proteins. Tectonic Therapeutic Inc., formerly known as AVROBIO Inc., is based in CAMBRIDGE, Mass. Number of Employees: 51

• Price / Volume Information    Yesterday's Closing Price: $21.72 Daily Weekly Monthly 20 Day Moving Average: 222,648 shares Shares Outstanding: 18.67 (millions) Market Capitalization: $405.57 (millions) Beta: 3.17 52 Week High: $61.07 52 Week Low: $13.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.21% -6.83% 12 Week 27.61% 7.34% Year To Date -52.96% -55.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 490 ARSENAL WAY SUITE 210 - WATERTOWN,MA 02472 USA ph: 339-666-3320 fax: - daniel@lifesciadvisors.com http://www.tectonictx.com

• General Corporate Information    Officers Alise Reicin - President; Chief Executive Officer and Director Daniel Lochner - Chief Financial Officer Terrance McGuire - Director Stefan Vitorovic - Director Timothy A. Springer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 878972108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 18.67 Most Recent Split Date: (:1) Beta: 3.17 Market Capitalization: $405.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -520.00% vs. Previous Quarter: -10.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -30.13 12/31/24 - -35.17 ROA 06/30/25 - - 03/31/25 - -27.52 12/31/24 - -31.61 Current Ratio 06/30/25 - - 03/31/25 - 22.92 12/31/24 - 12.65 Quick Ratio 06/30/25 - - 03/31/25 - 22.92 12/31/24 - 12.65 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 16.12 12/31/24 - 9.54 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.09 12/31/24 - 0.27

Powered by Zacks Investment Research ©